Rituximab (anti-CD20) therapy of B-cell lymphomas: Direct complement killing is superior to cellular effector mechanisms

Scandinavian Journal of Immunology

Volumn 51, Issue 6, 2000, Pages 634-641

  Harjunpaa A ^a   Junnikkala, S ^a   Meri, Seppo ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CD59 ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY BRIC 216; MONOCLONAL ANTIBODY BRIC 229; MONOCLONAL ANTIBODY CYB24; REGULATOR PROTEIN; RITUXIMAB; UNCLASSIFIED DRUG;

ANTIBODY SPECIFICITY; ARTICLE; B CELL LYMPHOMA; CANCER IMMUNOTHERAPY; COMPLEMENT DEPENDENT CYTOTOXICITY; DRUG MECHANISM; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD; ANTIGENS, CD20; ANTIGENS, CD46; ANTIGENS, CD55; ANTIGENS, CD59; ANTINEOPLASTIC AGENTS; APOPTOSIS; COMPLEMENT INACTIVATOR PROTEINS; COMPLEMENT SYSTEM PROTEINS; CYTOTOXICITY TESTS, IMMUNOLOGIC; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; LYMPHOMA, B-CELL; MEMBRANE GLYCOPROTEINS; TUMOR CELLS, CULTURED;

EID: 0034091481     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.2000.00745.x     Document Type: Article

References (29)

1. 1 Köhler G, Milstein C. Continuous culture of fused cells secreting antibody of predefined specifity. Nature 1975;256:495-6.
2. 2 Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435-45.
3. 3 Maloney D, Smith B, Appelbaum F. The anti-tumour effect of monoclonal anti-CD20 antibody therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma cell lines. Blood (Abstract Supplement) 1996;1:88.
4. 4 Gorter A, Meri S. Protection of tumour cells from immunological eradication by membrane-bound complement regulators. Immunol Today 1999;20:576-82.
5. 5 Nobutaka O, Shinichi S, Tedder T. CD20 Workshop Panel Report. In: Kishimoto T, eds. Leucocyte Typing VI. New York & London: Garland Publishing, Inc., 1997:135-7.
6. 6 Tedder TF, Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today 1994;15:450-4.
7. 7 Stashenko P, Nadler LM, Hardy R, et al. Expression of cell-surface markers after human B-lymphocyte activation. Proc Natl Acad Sci USA 1981;78:3848-52.
8. 2+ conductance found constitutively in B lymphocytes. J Cell Biol 1993;121:1121-32.
9. 9 Kanzaki M, Shibata H, Mogami H, et al. Expression of calcium-permeable cation channel CD20 accelerates progression through the G1 phase in Balb/c 3T3 cells. J Biol Chem 1995;270:13099-104.
10. 10 Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997;90:2188-95.
11. 11 McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal-antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-33.
12. 12 Vogel C-WM, Iler-Eberhard HJ. Induction of immune cytolysis: tumour-cell killing by complement is initiated by covalent complex of monoclonal antibody and stable C3/C5 convertase. Proc Natl Acad Sci USA 1981;78:7707-11.
13. 13 Morgan BP, Meri S. Membrane proteins that protect against complement lysis. Springer Semin Immunopathol 1994;15:369-96.
14. 14 Nicholson-Weller A, Burge J, Fearon DT, et al. Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system. J Immunol 1982;129:184-9.
15. 15 Pangburn MK, Schreiber RDM, Müller-Eberhard HJ. Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria. Proc Natl Acad Sci USA 1983;80:5430-4.
16. 16 Seya T, Turner JR, Atkinson JP. Purification and characterization of a membrane protein (gp45-70) that is a cofactor for cleavage of C3b and C4b. J Exp Med 1986;163:837-55.
17. 17 Sugita Y, Nakano Y, Tomita M. Isolation from human erythrocytes of a new membrane protein which inhibits the formation of complement transmembrane channels. J Biochem (Tokyo) 1988;104:633-7.
18. 18 Davies A, Simmons DL, Hale G, et al. CD59, an LY-6-like protein expressed in human-lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J Exp Med 1989;170:637-54.
19. 19 Meri S, Morgan BP, Davies A, et al. Human protectin (CD59), an 18, 000-20, 000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunol 1990;71:1-9.
20. 20 Rollins SA, Sims PJ. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9. J Immunol 1990;144:3478-83.
21. 21 Knuutila S, Klefström J, Szymanska J, et al. Two novel human B-cell lymphoma lines of lymphatic follicle origin: cytogenetic, molecular genetic and histopathological characterisation. Eur J Haemat 1994;52:65-72.
22. 22 Lehto T, Meri S. Interactions of soluble CD59 with the terminal complement complexes: CD59 and C9 compete for a nascent epitope on C8. J Immunol 1993;151:4941-9.
23. 23 Riethmüller G, Schneider-Gädicke E, Johnson JP. Monoclonal antibodies in cancer therapy. Curr Opin Immunol 1993;5:732-9.
24. 24 Houghton AN, Scheinherg D. Monoclonal antibodies in the treatment of hematopoietic malignancies. Semin Hematol 1988;25:23-9.
25. 25 LoBuglio A, Saleh M. Advances in monoclonal antibody therapy of cancer. Am J Med Sci 1992;304:214-24.
26. 26 Jain R. Determinants of tumour blood flow: a review. Cancer Res 1988;48:2641-58.
27. 27 Byrd JC, Waselenko JK, Maneatis TJ, et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumour cells: association with increased infusion-related side effects and rapid blood tumour clearance. J Clin Oncol 1999;17:791-5.
28. 28 Holliger P, Winter G. Engineering bispecific antibodies. Curr Opin Biotechnol 1993;4:446-9.
29. 29 Junnikkala S, Hakulinen J, Meri S. Targeted neutralization of the complement membrane attack complex inhibitor CD59 on the surface of human melanoma cells. Eur J Immunol 1994;24:611-5.